Rilzabrutinib (PRN1008) is a potent, selective, and orally bioavailable reversible covalent inhibitor of Brutons Tyrosine Kinase (BTK) with an IC50 of 1.3 nM. It is a research tool for investigating BTKs role in immunology and oncology, with applications in both in vitro biochemical assays and in vivo disease models.
